Gastrointestinal Collaboration and Licensing Deals 2016-2026

Key Benefits

✔ Benchmark against 438 gastrointestinal partnering deals – Access real-world collaboration and licensing activity to identify relevant precedents and comparable transactions.

✔ Benchmark gastrointestinal deal financials – Analyze disclosed headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.

✔ Identify prospective partners and leading dealmakers – Discover companies with demonstrated interest in gastrointestinal assets, technologies, therapeutic indications and relevant stages of development.

✔ Compare activity across the gastrointestinal landscape – Analyze dealmaking by therapeutic indication, development stage, technology type, deal type, industry sector and company.

✔ Find the most relevant comparable transactions – Move beyond broad averages to identify deals involving similar indications, technologies, development stages and partnering structures.

✔ Understand how gastrointestinal deals are structured – Examine licensing rights, development responsibilities, exclusivity, IP, commercialization rights, milestones, royalties and other important transaction provisions.

✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, obligations, financial terms and other negotiated provisions have been documented.

✔ Apply the intelligence to your own gastrointestinal opportunity – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own asset, indication, technology, prospective partners or transaction objectives.

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in gastrointestinal dealmaking

 

2.1. Introduction

2.2. Gastrointestinal partnering over the years     

2.3. Gastrointestinal partnering by deal type

2.4. Gastrointestinal partnering by industry sector

2.5. Gastrointestinal partnering by stage of development

2.6. Gastrointestinal partnering by technology type

2.7. Gastrointestinal partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for gastrointestinal partnering

 

3.1. Introduction

3.2. Disclosed financials terms for gastrointestinal partnering

3.3. Gastrointestinal partnering headline values

3.4. Gastrointestinal deal upfront payments

3.5. Gastrointestinal deal milestone payments

3.6. Gastrointestinal royalty rates

 

Chapter 4 – Leading gastrointestinal deals and dealmakers

 

4.1. Introduction

4.2. Most active in gastrointestinal partnering

4.3. List of most active dealmakers in gastrointestinal    

4.4. Top gastrointestinal deals by value

 

Chapter 5 – Gastrointestinal contract document directory

                                            

5.1. Introduction

5.2. Gastrointestinal partnering deals where contract document available

 

Chapter 6 – Gastrointestinal dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by gastrointestinal therapeutic target

 

Deal directory

 

Deal directory – Gastrointestinal deals by company A-Z

Deal directory – Gastrointestinal deals by technology type

 

Deal type definitions

 

About Biopharma Research Ltd

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Gastrointestinal partnering since 2016

Figure 2: Gastrointestinal partnering by deal type since 2016

Figure 3: Gastrointestinal partnering by industry sector since 2016

Figure 4: Gastrointestinal partnering by stage of development since 2016

Figure 5: Gastrointestinal partnering by technology type since 2016

Figure 6: Gastrointestinal partnering by indication since 2016

Figure 7: Gastrointestinal deals with a headline value

Figure 8: Gastrointestinal deals with upfront payment values

Figure 9: Gastrointestinal deals with milestone payment

Figure 10: Gastrointestinal deals with royalty rates

Figure 11: Active gastrointestinal dealmaking activity since 2016

Figure 12: Top gastrointestinal deals by value since 2016

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $7,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

4D Pharma, 4SC, 9 Meters Biopharma, Aayam Therapeutics, Abbvie, Ab E Discovery, Aclipse Therapeutics, AdaptivEndo, AdaptVac, Adiso Therapeutics, ADL Bionatur Solutions, Advanced Biological Laboratories, Aerpio Pharmaceuticals, Aevi Genomic Medicine, AgomAb Therapeutics, AIG Hospitals, AI Medical Service, Akebia Therapeutics, Alba Therapeutics, Alfasigma, Alimentiv, Alivio Therapeutics, Allergan, Allied Digestive Health, Alma Bio Therapeutics, Altos Group, Alvit LCS Pharma, Alvotech, Amarex Clinical Research, Ambry Genetics, Ambu, Amgen, AnimalBiome, Anokion, Antibe Therapeutics, Apogee Biotechnology, Applied BioMath, Arcadia Consumer Healthcare, Ardelyx, Arena Pharmaceuticals, Ariel Precision Medicine, Aristea Therapeutics, Artizan Biosciences, Asahi Kasei, AscentX Medical, Aslan Pharma, Assembly Biosciences, Associazione Poic e Dintorni APS, Astellas Pharma, AstraZeneca, Asymchem Laboratories, Athos Therapeutics, Atlantic Healthcare, Australasian Gastro Intestinal Research Foundation, Aziyo Biologics, AzurRx BioPharma, Back-A-Line, Bausch Health Companies, Baxter International, Bazelet, BDD Pharma, Beacon Discovery, BenevolentAI, Bharat Biotech, BigHat Biosciences, Bill and Melinda Gates Foundation, BinnoPharm, Bio-Me, Bio-Rad Laboratories, Bio-Thera Solutions, BioClinica, Biocodex Microbiota Foundation, BioDelivery Sciences, Biodexa Pharmaceuticals, Biofortis, Biogen, Biohaven Pharmaceuticals, Biolojic Design, BiomeBank, BioMed X Innovation Center, Biomerica, Biomica, BiomX, BioRap Technologies, Biostage, BioSurfaces, Boehringer Ingelheim, Boston Pharmaceuticals, Braintree Laboratories, Bridge Biotherapeutics, Brigham and Women's Hospital, Bristol-Myers Squibb, C4X Discovery, California Institute of Technology, Calypso Biotech, Camargo Pharmaceutical Services, CannaKids, Cannex Scientific, Cantel Medical, Capsulomics, Captor Therapeutics, Cara Care, Carbiotix, Case Western Reserve University, Catholic University Leuven, CB2 Therapeutics, Cedars-Sinai Medical Center, Celgene, Celiac Disease Foundation, Celltrion, Celsius Therapeutics, Censis Technologies, Cerevance, Cernostics, Charles River Laboratories, Cheplapharm Arzneimittel, Chime Biologics, Chinese University of Hong Kong, Chong Kun Dang, CHU Sainte-Justine, Cipher Pharmaceuticals, Cipla, Cleveland Clinic, Clinical Enterprise, CN Bio, Codexis, Collplant, ConvaTec, Cook Biotech, Cooper Pharma, Cornell University, Cosmo Pharmaceuticals, COUR Pharmaceutical, Creapharm, CRH Medical, Crohn's and Colitis Foundation of America, CRS Bio, Curant Health, CURE Pharmaceutical, Cyclerion Therapeutics, Cytocom, CytoReason, Daewoong Pharmaceutical, Daiichi Sankyo, Dalriada Drug Discovery, Danish Innovation Fund, DayTwo, Debiopharm, Deciphex, Delphi Genetics, Department of Defense, Dermira, Dignify Therapeutics, Diversigen, DNAnexus, Dong-A ST, Dr. Falk Pharma, Dr. Reddy's Laboratories, Duke Clinical Research Institute (DCRI), Duke University, EA Pharma, Earendil Labs, ECM Therapeutics, Eisai, Elanco, Eli Lilly, Emtora Biosciences, EndoLogic, enGene, Engitix, Ensho Therapeutics, Entera Health, Enterome Bioscience, Entrinsic Health Solutions, Equillium, EsoCap, Esteve, EtectRx, Eton Pharmaceuticals, Eunice Kennedy Shriver Institute of Child Health and Human Development, European Union, Evoke Pharma, Evolve BioSystems, Evommune, EVOQ Therapeutics, Evotec, Faes Farma, Felix Biotechnology, Ferring Pharmaceuticals, Finch Therapeutics, First Wave Bio, Food Marble Digestive Health, Formation Bio, Fosun Pharmaceutical, Foundation for Celiac Disease Outcome Measures, French National Institute for Agricultural Research, Fresenius Kabi Pharmaceuticals, FSD Pharma, Fujifilm Kyowa Kirin Biologics, Functional Gut Diagnostics, FutureGen Biopharm, Future Pak, Galapagos, Gedeon Richter, Genentech, Geneoscopy, General Automation Lab Technologies, Genetic Analysis, Genomic Biopharma, Genten Therapeutics, GentiBio, Georgia State University, Giiant Pharma, Gilead Sciences, Ginkgo BioWorks, GI OnDEMAND, GI Partners of Illinois, GI Reviewers, Gossamer Bio, Greenstone Biosciences, GSK, Gusto Global, Hadasit Bioholdings, Haisco Pharmaceutical, Halozyme Therapeutics, Harvest Capital Strategies, Helsinn Healthcare, Helsinn Therapeutics, Hepion Pharmaceuticals, HiFiBio, Highland Therapeutics, HK inno.N, Hollister-Stier Labs, Holobiome, Horizon Europe, Hoth Therapeutics, Hudson Institute of Medical Research, Hyloris Pharmaceuticals, I-mab, Iambic Therapeutics, Idera Pharmaceuticals, Illumina, IMIDomics, Immunai, Immune Pharmaceuticals, Immune Therapeutics, ImmuNext, Immunic, ImmunogenX, Imperial College London, InDex Pharmaceuticals, Innate Pharma, Innovate Biopharmaceuticals, Innovate UK, Innovation Pharmaceuticals, Innovet, Inotrem, InQpharm, Institut Gustave Roussy, Instituto de Ciencias Farmaceuticas, Intact Therapeutics, Intas Pharmaceuticals, International Centre for Diarrhoeal Disease Research, Intract Pharma, Intrexon, IntroMedic, InveniAI, Ionis Pharmaceuticals, Ipsen, IQVIA, Ironwood Pharmaceuticals, ISOThrive, Iterative Health, Iterative Scopes, Jaguar Health, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Sciences, Jiangsu Carephar Pharmaceutical, Jitsubo, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, JSR, Juntendo University, Juventas Therapeutics, Kaken Pharmaceutical, Kallyope, Kansas University Medical Center (KUMC), Karolinska Institute, Keio Gijuku University, Kenneth Rainin Foundation (KRF), Kings College London, Knight Therapeutics, Korea Pharma, Kwang Dong Pharmaceutical, Kyowa Hakko Kirin, Laboratories Acbel, Lahey Hospital & Medical Center, Lamassu Pharma, Landos Biopharma, Leona M and Harry B Helmsley Charitable Trust, Les Laboratoires Servier, LianBio, LimmaTech Biologics, LiveLeaf, LMU University Hospital Munich, LNC, Lucid Diagnostics, Luminex, Lupin, Lynx.MD, Mabwell Bioscience, Magellan Health Services, Marinomed Biotechnologie, Martin Pharmaceuticals, Massachusetts General Hospital, Massachusetts Institute of Technology, Mayo Clinic, McMaster University, Medgenics, MediBeacon, Medical University of Graz, Medical University of Vienna, MedImmune, Medtronic, Meiji Seika, Memorial Hermann Health System, Memorial Sloan Kettering Cancer Center, Merck and Co, Mesoblast, Metabiomics, Metabolon, Microba Life Sciences, Microbiotica, Millennium, Mimetas, Mission Cure, MiTest Health, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Monash University, Morphic Therapeutic, Mor Research Applications, Moss Genomics, Motus GI Medical Technologies, MultiPlan, Mundipharma, MyBiotics Pharma, Mylan Laboratories, Mylan Pharmaceuticals, Napo EU, Napo Pharmaceuticals, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Resilience, Nektar Therapeutics, Neolaia Bio, Neoteryx, Nestle Health Science, NeurAxis, Neurogastrx, New Day Diagnostics, Newsoara Biopharma, Nexilico, NexOptic, Nima, Nipro Corporation, Norgine, Northeastern University, Northwestern University, North Zealand University Hospital, Novartis, Novartis Institute for Tropical Diseases, Novome Biotechnologies, NuBiyota, Numab, NuMedii, Numerate, Nutricion, Nvidia, NYU Langone Medical Center, OMass Therapeutics, OmniVision Technologies, Onegevity, One GI, Orbis Medicines, OSE Immunotherapeutics, Otsuka America Pharmaceutical, Ovation, Owlstone Medical, Palisade Bio, Panaxia, Paragon Bioservices, Parexel, Parexel Biotech, Parvus Therapeutics, Path BioAnalytics, PAVmed, PEAR Therapeutics, Pendopharm, Penn State Microbiome Center, Pfizer, PharmaBiome, PharmaCare Management, PhaseV, Phathom Pharmaceuticals, PlantEXT, Pliant Therapeutics, Portal Instruments, PPD, Pragma Bio, Prana Biotechnology, PredictImmune, Premier Inc, Prescient Medical, Previse, PRISM BioLab, Probi, Processa Pharmaceuticals, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Proteic Bioscience, Provention Bio, PureTech Health, Purnovate, PvP Biologics, Quadri Pharmaceuticals, Qualicaps, Qu Biologics, Quell Therapeutics, Quotient Clinical, Quotient Therapeutics, Rafa Pharmaceuticals, Ramot at Tel Aviv University, Rani Therapeutics, Rasayana Therapeutics, Rebiotix, RedHill Biopharma, Regeneron Pharmaceuticals, Regentys, Renexxion, ReproCell, Rho, Ritter Pharmaceuticals, Roche, Roquette, Royal College of Surgeons (Ireland), Salix Pharmaceuticals, Samsung Bioepis, Sandoz, Sanofi, Sano Genetics, Satisfai Health, SciCann Therapeutics, Scipher Medicine, Sebela Pharmaceuticals, Second Genome, Seed Mena, Selexis, Seres Therapeutics, Serosep, Shandong Luoxin Pharma, Sheba Medical Center, Shionogi, Shire Pharmaceuticals, Siemens Healthineers, Signum Surgical, Simcere Pharmaceuticals, Simulations Plus, Sinorda Biomedicine, Sinovant Sciences, Siolta Therapeutics, SomaLogic, SonarMD, Sonoma BioTherapeutics, Sosei, Sosei Heptares, Spaulding Clinical Research, Stanford University School of Medicine, Starton Therapeutics, Statera Biopharma, Stella Diagnostics, Stoked Bio, Strand Life Sciences, Structural Genomics Consortium, Sun Genomics, SunRock Biopharma, Suono Bio, Sutter Health, Swiss Integrative Center for Human Health, Swixx Biopharma, Symbiotix Biotherapies, Synergy Pharmaceuticals, Synlogic, Synthetic Biologics, Synthon, Takeda Pharmaceutical, Tantu Therapeutics, TARGET PharmaSolutions, Telcon RF Pharmaceuticals, Tetra Bio-Pharma, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, Texas A&M Health Science Center, The Crohn's and Colitis Foundation of Canada, Theradiag, Theravance, Theravance Biopharma, Theriva Biologics, The Vancouver Island Health Authority, Thorne Research, TiGenix, Tissium, Tivic Health Systems, Tiziana Life Sciences, TScan Therapeutics, Twist Bioscience, Ubie, Unilever, UniQuest, United Digestive, Universite catholique de Louvain, University Gastroenterology, University Hospital of Leuven, University of Adelaide, University of Augsburg, University of Birmingham, University of British Columbia, University of Calgary, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Manitoba, University of Massachusetts, University of Michigan, University of North Carolina, University of Oslo, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Sherbrooke, University of Tokyo, University of Washington, University of Windsor, Upadia, US Government, Utrecht University, Valbiotis, Valneva, Vcell Healthcare, V ClinBio, VectivBio, Vedanta Biosciences, Verily, Vertex Pharmaceuticals, Viatris, VIPUN Medical, Virginia Catalyst, Virgo Surgical Video Solutions, Virios Therapeutics, Vital Food Processors, Vital Therapies, Vivante Health, Vivelix Pharmaceuticals, Vivtex, Vizient, Washington University in St Louis, WuXi Biologics, Yale University, Zealand Pharma, Zedira, Zentiva, Zydus Lifesciences

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

---

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

---

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements
• SEC filings and equivalent regulatory disclosures
• Company and investor presentations
• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

---

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development
• Research and collaborative R&D
• Manufacturing, supply, and distribution
• Commercialisation and co-promotion
• Equity investments, joint ventures, and asset transactions
• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

---

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties
• Rights allocation — development, manufacturing, and commercialization responsibilities
• Deal structure — exclusivity, territorial scope, and agreement type
• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type
• Stage of development
• Asset type and deal components
• Geographic scope and exclusivity
• Source documentation, including press releases and SEC filings

---

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

---

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered
• How responsibilities are operationalised between parties
• How flexibility, risk, and control are allocated within agreements

---

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

• Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
• Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
• Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

• Benchmarking comparable transactions
• Supporting valuation and deal structuring
• Preparing for negotiations
• Evaluating potential partners
• Informing internal strategy with real-world evidence

---

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.